Gheath Alatrash

Peer-Reviewed Articles

1. Oran B, Champlin RE, Wang F, Tanaka T, Saliba RM, Al-Atrash G, Garcia-Manero G, Kantarjian H, Cao K, Shpall EJ, Alousi AM, Mehta RS, Popat U, Futreal A, Takahashi K. Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation. Leukemia 36(1):257-262, 2022. e-Pub 2021. PMID: 34135465.
2. Mehta RS, Bassett R, Chen J, Valdez BC, Kawedia J, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Qazilbash MH, Ramdial J, Saini N, Srour SA, Rezvani K, Shpall EJ, Andersson BS, Champlin RE, Popat UR. Myeloablative Fractionated Busulfan With Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial. Transplant Cell Ther 27(11):913.e1-913.e12, 2021. e-Pub 2021. PMID: 34329753.
3. Lu S, Tallis E, Ding X, Li D, Cox K, You MJ, St John L, Alatrash G, Ma Q, Molldrem JJ. Novel myeloperoxidase-derived HLA-A2-restricted peptides as therapeutic targets against myeloid leukemia. Cytotherapy 23(9):793-798, 2021. e-Pub 2021. PMID: 34215503.
4. Yalniz FF, Saliba RM, Greenbaum U, Ramdial J, Popat U, Oran B, Alousi A, Olson A, Alatrash G, Marin D, Rezvani K, Hosing C, Im J, Mehta R, Qazilbash M, Joseph JJ, Rondon G, Kanagal-Shamanna R, Shpall E, Champlin R, Kebriaei P. Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Myeloid Leukemia. Transplant Cell Ther 27(8):689-695, 2021. e-Pub 2021. PMID: 34023569.
5. Olson A, Lin R, Marin D, Rafei H, Bdaiwi MH, Thall PF, Basar R, Abudayyeh A, Banerjee P, Aung FM, Kaur I, Abueg G, Rao S, Chemaly R, Mulanovich V, Al-Atrash G, Alousi AM, Andersson BS, Anderlini P, Bashir Q, Castro KM, Daher M, Galvan IM, Hosing C, Im JS, Jones RB, Kebriaei P, Khouri I, Mehta R, Molldrem J, Nieto Y, Oran B, Popat U, Qazilbash M, Rondon G, Saini N, Spencer B, Srour S, Washington D, Barnett M, Champlin RE, Shpall EJ, Rezvani K. Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. J Clin Oncol 39(24):2710-2719, 2021. e-Pub 2021. PMID: 33929874.
6. Yam C, Yen EY, Chang JT, Bassett RL, Alatrash G, Garber H, Huo L, Yang F, Philips AV, Ding QQ, Lim B, Ueno NT, Kannan K, Sun X, Sun B, Parra Cuentas ER, Symmans WF, White JB, Ravenberg E, Seth S, Guerriero JL, Rauch GM, Damodaran S, Litton JK, Wargo JA, Hortobagyi GN, Futreal A, Wistuba II, Sun R, Moulder SL, Mittendorf EA. Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer. Clin Cancer Res. e-Pub 2021. PMID: 34253579.
7. Herbrich S, Baran N, Cai T, Weng C, Aitken MJL, Post SM, Henderson J, Shi C, Richard-Carpentier G, Sauvageau G, Baggerly K, Al-Atrash G, Davis RE, Daver N, Zha D, Konopleva M. Overexpression of CD200 is a Stem Cell-Specific Mechanism of Immune Evasion in AML. J Immunother Cancer 9(7), 2021. PMID: 34326171.
8. Reville PK, Kantarjian HM, Ravandi F, Jabbour E, DiNardo CD, Daver N, Pemmaraju N, Ohanian M, Alvarado Y, Xiao L, Alatrash G, Loghavi S, Rausch CR, Borthakur G, Konopleva M, Cortes J, Kadia TM. Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study. Blood Cancer J 11(3):60, 2021. e-Pub 2021. PMID: 33731681.
9. Saberian C, Abdel-Wahab N, Abudayyeh A, Rafei H, Joseph J, Rondon G, Whited L, Gruschkus S, Fa'ak F, Daher M, Knape C, Safa H, Shoukier M, Suarez-Almazor ME, Marcotulli M, Ludford K, Gulbis AM, Konopleva M, Ohanian M, Ravandi F, Garcia-Manero G, Oran B, Popat UR, Mehta R, Alousi AM, Daver N, Champlin R, Diab A, Al-Atrash G. Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation. J Immunother Cancer 9(2), 2021. PMID: 33637601.
10. Saliba RM, Veltri L, Rondon G, Chen J, Al-Atrash G, Alousi A, Martinez C, Augustine L, Hosing CM, Oran B, Rezvani K, Shpall EJ, Kebriaei P, Khouri IF, Popat U, Champlin RE, Ciurea SO. Impact of graft composition on outcomes of haploidentical bone marrow stem cell transplantation. Haematologica 106(1):269-274, 2021. e-Pub 2021. PMID: 32107328.
11. Oran B, Garcia-Manero G, Saliba RM, Alfayez M, Al-Atrash G, Ciurea SO, Jabbour EJ, Mehta RS, Popat UR, Ravandi F, Alousi AM, Kadia TM, Konopleva M, DiNardo CD, Rezvani K, Shpall EJ, Sharma P, Kantarjian HM, Champlin RE, Daver N. Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors. Cancer 126(10):2193-2205, 2020. e-Pub 2020. PMID: 32125707.
12. Mehta RS, Bassett R, Olson A, Chen J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Molldrem JJ, Nieto Y, Oran B, Rezvani K, Qazilbash MH, Srour SA, Shpall EJ, Andersson BS, Champlin RE, Popat UR. Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial. Haematologica 104(12):e555-e557, 2019. e-Pub 2019. PMID: 30948491.
13. Srour SA, Saliba RM, Bittencourt MCB, Perez JMR, Kongtim P, Alousi A, Al-Atrash G, Olson A, Betul O, Mehta R, Popat U, Hosing C, Bashir Q, Khouri I, Kebriaei P, Masarova L, Short N, Jabbour E, Daver N, Konopleva M, Ravandi F, Kantarjian H, Champlin RE, Ciurea SO. Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation. Am J Hematol 94(12):1382-1387, 2019. e-Pub 2019. PMID: 31595538.
14. Alatrash G, Kidwell KM, Thall PF, Di Stasi A, Chen J, Zope M, Crain AK, Champlin RE, Popat U, Shpall EJ, Jones RB, Andersson BS. Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS. Bone Marrow Transplant 54(8):1245-1253, 2019. e-Pub 2018. PMID: 30532055.
15. Chamoun K, Milton DR, Ledesma C, Young KH, Jabbour EJ, Alatrash G, Anderlini P, Bashir Q, Ciurea SO, Marin D, Molldrem JJ, Olson AL, Oran B, Popat UR, Rondon G, Champlin RE, Gulbis AM, Khouri IF. Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results. Biol Blood Marrow Transplant 25(7):1347-1354, 2019. e-Pub 2019. PMID: 30826465.
16. Alatrash G, Qiao N, Zhang M, Zope M, Perakis AA, Sukhumalchandra P, Philips AV, Garber HR, Kerros C, St John LS, Khouri MR, Khong H, Clise-Dwyer K, Miller LP, Wolpe S, Overwijk WW, Molldrem JJ, Ma Q, Shpall EJ, Mittendorf EA. Fucosylation Enhances the Efficacy of Adoptively Transferred Antigen-Specific Cytotoxic T Lymphocytes. Clin Cancer Res 25(8):2610-2620, 2019. e-Pub 2019. PMID: 30647079.
17. Ciurea SO, Bittencourt MCB, Milton DR, Cao K, Kongtim P, Rondon G, Chen J, Konopleva M, Perez JMR, El Shazly MF, Aljadayeh M, Alvarez M, Im J, Al-Atrash G, Mehta R, Popat U, Bashir Q, Oran B, Hosing CM, Khouri IF, Kebriaei P, Champlin RE. Is a matched unrelated donor search needed for all allogeneic transplant candidates?. Blood Advances 2(17):2254-2261, 2018. PMID: 30206098.
18. Kongtim P, Parmar S, Milton DR, Perez JMR, Rondon G, Chen J, Chilkulwar AR, Al-Atrash G, Alousi A, Andersson BS, Im JS, Hosing CM, Bashir Q, Khouri I, Kebriaei P, Oran B, Popat U, Champlin R, Ciurea SO. Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant, 2018. PMID: 30258129.
19. Yang TH, St John LS, Garber HR, Kerros C, Ruisaard KE, Clise-Dwyer K, Alatrash G, Ma Q, Molldrem JJ. Membrane-Associated Proteinase 3 on Granulocytes and Acute Myeloid Leukemia Inhibits T Cell Proliferation. J Immunol 201(5):1389-1399, 2018. e-Pub 2018. PMID: 30021768.
20. Lansford JL, Dharmasiri U, Chai S, Hunsucker SA, Bortone DS, Keating JE, Schlup IM, Glish GL, Collins EJ, Alatrash G, Molldrem JJ, Armistead PM, Vincent BG. Computational modeling and confirmation of leukemia-associated minor histocompatibility antigens. Blood Advances 2(16):2052-2062, 2018. PMID: 30115642.
21. Alatrash G, Perakis AA, Kerros C, Peters HL, Sukhumalchandra P, Zhang M, Jakher H, Zope M, Patenia R, Sergeeva A, Yi S, Young KH, Philips AV, Cernosek AM, Garber HR, Qiao N, Weng J, St John LS, Lu S, Clise-Dwyer K, Mittendorf EA, Ma Q, Molldrem JJ. Targeting the Leukemia Antigen PR1 with Immunotherapy for the Treatment of Multiple Myeloma. Clin Cancer Res 24(14):3386-3396, 2018. e-Pub 2018. PMID: 29661776.
22. Vreeland TJ, Litton JK, Qiao N, Philips AV, Alatrash G, Hale DF, Jackson DO, Peace KM, Greene JM, Berry JS, Clifton GT, Peoples GE, Mittendorf EA. Phase Ib trial of folate binding protein (FBP)-derived peptide vaccines, E39 and an attenuated version, E39': An analysis of safety and immune response. Clin Immunol 192:6-13, 2018. e-Pub 2018. PMID: 29574039.
23. Molina JR, Sun Y, Protopopova M, Gera S, Bandi M, Bristow C, McAfoos T, Morlacchi P, Ackroyd J, Agip AA, Al-Atrash G, Asara J, Bardenhagen J, Carrillo CC, Carroll C, Chang E, Ciurea S, Cross JB, Czako B, Deem A, Daver N, de Groot JF, Dong JW, Feng N, Gao G, Gay J, Do MG, Greer J, Giuliani V, Han J, Han L, Henry VK, Hirst J, Huang S, Jiang Y, Kang Z, Khor T, Konoplev S, Lin YH, Liu G, Lodi A, Lofton T, Ma H, Mahendra M, Matre P, Mullinax R, Peoples M, Petrocchi A, Rodriguez-Canale J, Serreli R, Shi T, Smith M, Tabe Y, Theroff J, Tiziani S, Xu Q, Zhang Q, Muller F, DePinho RA, Toniatti C, Draetta GF, Heffernan TP, Konopleva M, Jones P, Di Francesco ME, Marszalek JR.. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nature Medicine, 2018. PMID: 29892070.
24. Ciurea SO, Chilkulwar A, Saliba RM, Chen J, Rondon G, Patel KP, Khogeer H, Shah AR, Randolph BV, Ramos Perez JM, Popat U, Hosing CM, Bashir Q, Mehta R, Al-Atrash G, Im J, Khouri IF, Kebriaei P, Champlin RE. Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with TP53 mutations. Blood. e-Pub 2018. PMID: 29769261.
25. Chahoud J, Sui D, Erwin WD, Gulbis AM, Korbling M, Zhang M, Ahmed S, Alatrash G, Anderlini P, Ciurea SO, Oran B, Fayad LE, Bassett RL, Jabbour EJ, Medeiros LJ, Macapinlac HA, Young KH, Khouri IF. Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma. Clin Cancer Res 24(10):2304-2311, 2018. e-Pub 2018. PMID: 29476021.
26. Alatrash G, Molldrem JJ, Qazilbash MH. Targeting PR1 in myeloid leukemia. Oncotarget 9(4):4280-4281, 2018. e-Pub 2017. PMID: 29435102.
27. Herrmann AC, Im JS, Pareek S, Ruiz-Vasquez W, Lu S, Sergeeva A, Mehrens J, He H, Alatrash G, Sukhumalchandra P, St John L, Clise-Dwyer K, Zha D, Molldrem JJ. A Novel T-Cell Engaging Bi-specific Antibody Targeting the Leukemia Antigen PR1/HLA-A2. Front Immunol 9:3153, 2018. e-Pub 2019. PMID: 30713535.
28. Gall VA, Philips AV, Qiao N, Clise-Dwyer K, Perakis AA, Zhang M, Clifton GT, Sukhumalchandra P, Ma Q, Reddy SM, Yu D, Molldrem JJ, Peoples GE, Alatrash G, Mittendorf EA. Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells. Cancer Res 77(19):5374-5383, 2017. e-Pub 2017. PMID: 28819024.
29. Clifton GT, Litton JK, Arrington K, Ponniah S, Ibrahim NK, Gall V, Alatrash G, Peoples GE, Mittendorf EA. Results of a Phase Ib Trial of Combination Immunotherapy with a CD8+ T Cell Eliciting Vaccine and Trastuzumab in Breast Cancer Patients. Ann Surg Oncol 24(8):2161-2167, 2017. e-Pub 2017. PMID: 28315060.
30. Battula VL, Le PM, Sun JC, Nguyen K, Yuan B, Zhou X, Sonnylal S, McQueen T, Ruvolo V, Michel KA, Ling X, Jacamo R, Shpall E, Wang Z, Rao A, Al-Atrash G, Konopleva M, Davis RE, Harrington MA, Cahill CW, Bueso-Ramos C, Andreeff M. AML-induced osteogenic differentiation in mesenchymal stromal cells supports leukemia growth. JCI Insight 2(13). e-Pub 2017. PMID: 28679949.
31. Kerros C, Tripathi SC, Zha D, Mehrens JM, Sergeeva A, Philips AV, Qiao N, Peters HL, Katayama H, Sukhumalchandra P, Ruisaard KE, Perakis AA, St John LS, Lu S, Mittendorf EA, Clise-Dwyer K, Herrmann AC, Alatrash G, Toniatti C, Hanash SM, Ma Q, Molldrem JJ. Neuropilin-1 mediates Neutrophil Elastase uptake and cross-presentation in breast cancer cells. J Biol Chem 292(24):10295-10305, 2017. e-Pub 2017. PMID: 28468826.
32. Peters HL, Tripathi SC, Kerros C, Katayama H, Garber HR, St John LS, Federico L, Meraz IM, Roth JA, Sepesi B, Majidi M, Ruisaard K, Clise-Dwyer K, Roszik J, Gibbons DL, Heymach JV, Swisher SG, Bernatchez C, Alatrash G, Hanash S, Molldrem JJ. Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells. Cancer Immunol Res 5(4):319-329, 2017. e-Pub 2017. PMID: 28254787.
33. Andersson BS, Thall PF, Valdez BC, Milton DR, Al-Atrash G, Chen J, Gulbis A, Chu D, Martinez C, Parmar S, Popat U, Nieto Y, Kebriaei P, Alousi A, de Lima M, Rondon G, Meng QH, Myers A, Kawedia J, Worth LL, Fernandez-Vina M, Madden T, Shpall EJ, Jones RB, Champlin RE. Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients. Bone Marrow Transplant 52(4):580-587, 2017. e-Pub 2016. PMID: 27991894.
34. Qazilbash MH, Wieder E, Thall PF, Wang X, Rios R, Lu S, Kanodia S, Ruisaard KE, Giralt SA, Estey EH, Cortes J, Komanduri KV, Clise-Dwyer K, Alatrash G, Ma Q, Champlin RE, Molldrem JJ. PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies. Leukemia 31(3):697-704, 2017. e-Pub 2016. PMID: 27654852.
35. Badar T, Srour S, Bashir Q, Shah N, Al-Atrash G, Hosing C, Popat U, Nieto Y, Orlowski RZ, Champlin R, Qazilbash MH. Predictors of inferior clinical outcome in patients with standard-risk multiple myeloma. Eur J Haematol 98(3):263-268, 2017. e-Pub 2016. PMID: 27862330.
36. Alatrash G, Garber HR, Zhang M, Sukhumalchandra P, Qiu Y, Jakher H, Perakis AA, Becker L, Yoo SY, Dwyer KC, Coombes K, Talukder AH, John LSS, Senyukov V, Lee DA, Sergeeva A, He H, Ma Q, Armistead PM, Roszik J, Mittendorf EA, Molldrem JJ, Hawke D, Lizee G, Kornblau SM. Cathepsin G is broadly expressed in acute myeloid leukemia and is an effective immunotherapeutic target. Leukemia 31(1):234-237, 2017. e-Pub 2016. PMID: 27573556.
37. Khouri IF, Sui D, Jabbour EJ, Samuels BI, Turturro F, Alatrash G, Anderlini P, Ahmed S, Oran B, Ciurea SO, Marin D, Olson A, Patel KK, Popat UR, Ledesma C, Kadia TM, Ferrajoli A, Burger JA, Jorgensen JL, Medeiros LJ, Bassett RL, Gulbis AM. Bendamustine added to allogeneic conditioning improves long-term outcomes in patients with CLL. Bone Marrow Transplant 52(1):28-33, 2017. e-Pub 2016. PMID: 27595282.
38. Han L, Jorgensen JL, Brooks C, Shi C, Zhang Q, Nogueras González GM, Cavazos A, Pan R, Mu H, Wang S, Zhou J, Alatrash G, Ciurea SO, Rettig M, DiPersio JF, Cortes JE, Huang X, Kantarjian H, Andreeff M, Ravandi-Kashani F, Konopleva M. Anti-leukemia efficacy and mechanisms of action of SL-101, a novel anti-CD123 antibody-conjugate, in acute myeloid leukemia. Clin Cancer Res. e-Pub 2017. PMID: 28096272.
39. Khan M, Carmona S, Sukhumalchandra P, Roszik J, Philips A, Perakis AA, Kerros C, Zhang M, Qiao N, John LSS, Zope M, Goldberg J, Qazilbash M, Jakher H, Clise-Dwyer K, Qiu Y, Mittendorf EA, Molldrem JJ, Kornblau SM, Alatrash G. Cathepsin G Is Expressed by Acute Lymphoblastic Leukemia and Is a Potential Immunotherapeutic Target. Front Immunol 8:1975, 2017. e-Pub 2018. PMID: 29422892.
40. Gaballa S, Ge I, El Fakih R, Brammer JE, Kongtim P, Tomuleasa C, Wang SA, Lee D, Petropoulos D, Cao K, Rondon G, Chen J, Hammerstrom A, Lombardi L, Alatrash G, Korbling M, Oran B, Kebriaei P, Ahmed S, Shah N, Rezvani K, Marin D, Bashir Q, Alousi A, Nieto Y, Qazilbash M, Hosing C, Popat U, Shpall EJ, Khouri I, Champlin RE, Ciurea SO. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. Cancer 122(21):3316-3326, 2016. e-Pub 2016. PMID: 27404668.
41. Alatrash G, Daver N, Mittendorf EA. Targeting Immune Checkpoints in Hematologic Malignancies. Pharmacol Rev 68(4):1014-1025, 2016. PMID: 27664133.
42. Sergeeva A, He H, Ruisaard K, St John L, Alatrash G, Clise-Dwyer K, Li D, Patenia R, Hong R, Sukhumalchandra P, You MJ, Gagea M, Ma Q, Molldrem JJ. Activity of 8F4, a T cell Receptor-like Anti-PR1/HLA-A2 Antibody, Against Primary Human AML in vivo. Leukemia 30(7):1475-84, 2016. e-Pub 2016. PMID: 27055866.
43. Chawla A, Alatrash G, Philips AV, Qiao N, Sukhumalchandra P, Kerros C, Diaconu I, Gall V, Neal S, Peters HL, Clise-Dwyer K, Molldrem JJ, Mittendorf EA. Neutrophil elastase enhances antigen presentation by upregulating human leukocyte antigen class I expression on tumor cells. Cancer Immunol Immunother 65(6):741-51, 2016. e-Pub 2016. PMID: 27129972.
44. Bayraktar UD, Milton DR, Guindani M, Rondon G, Chen J, Al-Atrash G, Rezvani K, Champlin R, Ciurea SO. Optimal Threshold and Time of Absolute Lymphocyte Count Assessment for Outcome Prediction after Bone Marrow Transplantation. Biol Blood Marrow Transplant 22(3):505-13, 2016. e-Pub 2015. PMID: 26524730.
45. Lee HC, Saliba RM, Rondon G, Chen J, Charafeddine Y, Medeiros LJ, Alatrash G, Andersson BS, Popat U, Kebriaei P, Ciurea S, Oran B, Shpall E, Champlin R. Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes. Biol Blood Marrow Transplant 21(11):1948-54, 2015. e-Pub 2015. PMID: 26183077.
46. Alousi AM, Brammer JE, Saliba RM, Andersson B, Popat U, Hosing C, Jones R, Shpall EJ, Khouri I, Qazilbash M, Nieto Y, Shah N, Ahmed S, Oran B, Al Atrash G, Ciurea S, Kebriaei P, Chen J, Rondon G, Champlin RE. Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies. Biol Blood Marrow Transplant 21(5):906-12, 2015. e-Pub 2015. PMID: 25667989.
47. Hunsucker SA, McGary CS, Vincent BG, Enyenihi AA, Waugh JP, McKinnon KP, Bixby LM, Ropp PA, Coghill JM, Wood WA, Gabriel DA, Sarantopoulos S, Shea TC, Serody JS, Alatrash G, Rodriguez-Cruz T, Lizée G, Buntzman AS, Frelinger JA, Glish GL, Armistead PM. Peptide/MHC tetramer based sorting of CD8+ T cells to a leukemia antigen yields clonotypes drawn nonspecifically from an underlying restricted repertoire. Cancer Immunol Res 3(3):228-35, 2015. e-Pub 2015. PMID: 25576336.
48. Di Stasi A, Milton DR, Poon LM, Hamdi A, Rondon G, Chen J, Pingali SR, Konopleva M, Kongtim P, Alousi A, Qazilbash MH, Ahmed S, Bashir Q, Al-atrash G, Oran B, Hosing CM, Kebriaei P, Popat U, Shpall EJ, Lee DA, de Lima M, Rezvani K, Khouri IF, Champlin RE, Ciurea SO. Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors. Biol Blood Marrow Transplant 20(12):1975-81, 2014. e-Pub 2014. PMID: 25263628.
49. Tang X, Alatrash G, Ning J, Jakher H, Stafford P, Zope M, Shpall EJ, Jones RB, Champlin RE, Thall PF, Andersson BS. Increasing Chimerism after Allogeneic Stem Cell Transplantation Is Associated with Longer Survival Time. Biol Blood Marrow Transplant 20(8):1139-44, 2014. e-Pub 2014. PMID: 24727332.
50. Garber HR, Mirza A, Mittendorf EA, Alatrash G.. Adoptive T-cell therapy for Leukemia. Molecular and Cellular Therapies, 2014.
51. Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM, Akcakanat A, Chawla A, Curran M, Hwu P, Sharma P, Litton JK, Molldrem JJ, Alatrash G. PD-L1 Expression in Triple-Negative Breast Cancer. Cancer Immunol Res 2(4):361-70, 2014. e-Pub 2014. PMID: 24764583.
52. Zhang M, Sukhumalchandra P, Enyenihi AA, St John LS, Hunsucker SA, Mittendorf EA, Sergeeva A, Ruisaard K, Al-Atrache Z, Ropp PA, Jakher H, Rodriguez-Cruz T, Lizee G, Clise-Dwyer K, Lu S, Molldrem JJ, Glish GL, Armistead PM, Alatrash G. A Novel HLA-A*0201 Restricted Peptide Derived From Cathepsin G Is An Effective Immunotherapeutic Target in Acute Myeloid Leukemia. Clin Cancer Res 19(1):247-57, 2013. e-Pub 2012. PMID: 23147993.
53. Alatrash G, Mittendorf EA, Sergeeva A, Sukhumalchandra P, Qiao N, Zhang M, St John LS, Ruisaard K, Haugen CE, Al-Atrache Z, Jakher H, Philips AV, Ding X, Chen JQ, Wu Y, Patenia RS, Bernatchez C, Vence LM, Radvanyi LG, Hwu P, Clise-Dwyer K, Ma Q, Lu S, Molldrem JJ. Broad Cross-Presentation of the Hematopoietically-Derived PR1 Antigen on Solid Tumors Leads to Susceptibility to PR1-Targeted Immunotherapy. J Immunol 189(11):5476-84, 2012. e-Pub 2012. PMID: 23105141.
54. Ciurea SO, Mulanovich V, Saliba RM, Bayraktar UD, Jiang Y, Bassett R, Wang SA, Konopleva M, Fernandez-Vina M, Montes N, Bosque D, Chen J, Rondon G, Alatrash G, Alousi A, Bashir Q, Korbling M, Qazilbash M, Parmar S, Shpall E, Nieto Y, Hosing C, Kebriaei P, Khouri I, Popat U, de Lima M, Champlin RE. Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 18(12):1835-44, 2012. e-Pub 2012. PMID: 22796535.
55. Mittendorf EA, Alatrash G, Qiao N, Wu Y, Sukhumalchandra P, St John LS, Philips AV, Xiao H, Zhang M, Ruisaard K, Clise-Dwyer K, Lu S, Molldrem JJ. Breast cancer cell uptake of the inflammatory mediator neutrophil elastase triggers an anti-cancer adaptive immune response. Cancer Res 72(13):3153-62, 2012. e-Pub 2012. PMID: 22564522.
56. Alatrash G, Ono Y, Sergeeva A, Sukhumalchandra P, Zhang M, St John LS, Yang TH, Ruisaard K, Armistead PM, Mittendorf EA, He H, Qiao N, Rodriguez-Cruz T, Liang S, Clise-Dwyer K, Wieder ED, Lizee G, Lu S, Molldrem JJ. The Role of Antigen Cross-presentation From Leukemia Blasts on Immunity to the Leukemia-associated Antigen PR1. J Immunother 35(4):309-20, 2012. PMID: 22495388.
57. Alatrash G, Pelosini M, Saliba RM, Koca E, Rondon G, Andersson BS, Chiattone A, Zhang W, Giralt SA, Cernosek AM, Kebriaei P, Alousi AM, Popat UR, Hosing C, Khouri IF, Champlin RE, de Lima MJ. Platelet recovery before allogeneic stem cell transplantation predicts posttransplantation outcomes in patients with acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant 17(12):1841-5, 2011. e-Pub 2011. PMID: 21684343.
58. Alatrash G, de Lima M, Hamerschlak N, Pelosini M, Wang X, Xiao L, Kerbauy F, Chiattone A, Rondon G, Qazilbash MH, Giralt SA, de Padua Silva L, Hosing C, Kebriaei P, Zhang W, Nieto Y, Saliba RM, Champlin RE, Andersson BS. Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life. Biol Blood Marrow Transplant 17(10):1490-6, 2011. e-Pub 2011. PMID: 21338705.
59. Weng J, Cha SC, Matsueda S, Alatrash G, Popescu MS, Yi Q, Molldrem JJ, Wang M, Neelapu SS, Kwak LW. Targeting human B-cell malignancies through Ig light chain specific cytotoxic T lymphocytes. Clin Cancer Res 17(18):5945-52, 2011. e-Pub 2011. PMID: 21813633.
60. Mittendorf EA, Alatrash G, Xiao H, Clifton GT, Murray JL, Peoples GE. Breast cancer vaccines: ongoing National Cancer Institute-registered clinical trials. Expert Rev Vaccines 10(6):755-74, 2011. PMID: 21692698.
61. Sergeeva A, Alatrash G, He H, Ruisaard K, Lu S, Wygant J, McIntyre BW, Ma Q, Li D, St John L, Clise-Dwyer K, Molldrem JJ. An Anti-PR1/HLA-A2 T Cell Receptor-Like Antibody Mediates Complement Dependent Cytotoxicity Against Acute Myeloid Leukemia Progenitor Cells. Blood 117(16):4262-72, 2011. e-Pub 2011. PMID: 21296998.
62. Alatrash G, Molldrem JJ. Vaccines as consolidation therapy for myeloid leukemia. Expert Rev Hematol 4(1):37-50, 2011. PMID: 21322777.
63. Armistead PM, Liang S, Li H, Lu S, Van Bergen CA, Alatrash G, St John L, Hunsucker SA, Sarantopoulos S, Falkenburg JH, Molldrem JJ. Common minor histocompatibility antigen discovery based upon patient clinical outcomes and genomic data. PLoS One 6(8):e23217, 2011. e-Pub 2011. PMID: 21858034.
64. Ma Q, Wang C, Jones D, Quintanilla KE, Li D, Wang Y, Wieder ED, Clise-Dwyer K, Alatrash G, Mj Y, Munsell MF, Lu S, Qazilbash MH, Molldrem JJ. Adoptive transfer of PR1 cytotoxic T lymphocytes associated with reduced leukemia burden in a mouse acute myeloid leukemia xenograft model. Cytotherapy 12(8):1056-62, 2010. e-Pub 2010. PMID: 20735170.
65. Armistead PM, Wieder E, Akande O, Alatrash G, Quintanilla K, Liang S, Molldrem J. Cyclic neutropenia associated with T cell immunity to granulocyte proteases and a double de novo mutation in GFI1, a transcriptional regulator of ELANE. Br J Haematol 150(6):716-9, 2010. PMID: 20560965.
66. Kanodia S, Wieder E, Lu S, Talpaz M, Alatrash G, Clise-Dwyer K, Molldrem JJ. PR1-Specific T Cells are associated with unmaintained cytogenetic remission of chronic myelogenous leukemia after interferon withdrawal. PLoS One 5(7):e11770, 2010. e-Pub 2010. PMID: 20668669.
67. Alatrash G, Albitar M, O'Brien S, Wang X, Manshouri T, Faderl S, Ferrajoli A, Burger J, Garcia-Manero G, Kantarjian HM, Lerner S, Keating MJ, Wierda WG. Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR). Br J Haematol 148(3):386-93, 2010. e-Pub 2009. PMID: 19895616.
68. Alatrash G, Molldrem JJ. Immunotherapy of AML. Cancer Treat Res 145:237-55, 2010. PMID: 20306255.
69. Alatrash G, Majhail NS, Pile JC. Rhabdomyolysis following the ingestion of 'Foxy'. Mayo Clin Proc 81(4):550-1, 2006. PMID: 16610577.
70. Alatrash G, Hutson TE, Molto L, Richmond A, Nemec C, Mekhail T, Elson P, Tannenbaum C, Olencki T, Finke J, Bukowski RM. Clinical and immunologic effects of subcutaneously administered IL-12 and IFN-a2b: Phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma. J Clin Oncol 22(14):2891-900, 2004. PMID: 15254058.
71. Datta A, Kitson RP, Xue Y, al-Atrash G, Mazar AP, Jones TR, Goldfarb RH. Combined chemo/anti-angiogenic cancer therapy against Lewis lung carcinoma (3LL) pulmonary metastases. In Vivo 16(6):451-7, 2002. PMID: 12494889.
72. Al-Atrash G, Shetty S, Idell S, Xue Y, Kitson RP, Halady PK, Goldfarb RH. IL-2-mediated upregulation of uPA and uPAR in natural killer cells. Biochem Biophys Res Commun 292(1):184-9, 2002. PMID: 11890690.
73. Al-Atrash G, Kitson RP, Xue Y, Mazar AP, Kim MH, Goldfarb RH. uPA and uPAR contribute to NK cell invasion through the extracellular matrix. Anticancer Res 21(3B):1697-704, 2001. PMID: 11497249.
74. Al-Atrash G, Kitson RP, Xue Y, Goldfarb RH. Cooperation of urokinase plasminogen activator and matrix metalloproteinases in NK cell invasion. In Vivo 14(5):565-70, 2000. PMID: 11125540.
75. Goldfarb RH, Koelemij R, Muirhead KA, Ohlsson-Wilhelm BM, Gray BD, Kuppen PJ, Basse PH, al-Atrash G, Kitson RP. A novel drug delivery system using IL-2 activated NK cells and Zyn-linked doxorubicin. In Vivo 14(1):101-4, 2000. PMID: 10757065.

Invited Articles

1. Chawla A, Philips AV, Alatrash G, Mittendorf E. Immune checkpoints: A therapeutic target in triple negative breast cancer. Oncoimmunology 3(3):e28325, 2014. e-Pub 2014. PMID: 24843833.
2. Garber HR, Mirza A, Mittendorf EA, Alatrash G. Adoptive T-cell Therapy for Leukemia. Mol Cell Ther 2(25):25, 2014. e-Pub 2014. PMID: 26056592.
3. Alatrash G, Jakher H, Stafford PD, Mittendorf EA. Cancer immunotherapies, their safety and toxicity. Expert Opin Drug Saf 12(5):631-45, 2013. e-Pub 2013. PMID: 23668362.
4. Chawla A, Alatrash G, Wu Y, Mittendorf EA. Immune aspects of the breast tumor microenvironment. Breast Cancer Manag 2(3):231-244, 2013. PMID: 24516507.
5. Alatrash G. Targeting cathepsin G in myeloid leukemia. Oncoimmunology 2(4):e23442, 2013. PMID: 23734308.
6. Molldrem JJ, Alatrash G. Immune rage against MAGE unleashed. Blood 116(11):1824-5, 2010. PMID: 20847207.

Other Articles

1. Alatrash G, Wierda W Multiple articles covering ASH Annual Meeting 2006. ASH Daily News, 2006.
2. Alatrash G, Kim ES Treatment of advanced non-small-cell lung cancer: First-line therapy and future directions. Oncology Special Edition 9:35-40, 2006.
3. Wierda W, Schlette E, Alatrash G Initial treatment of chronic lymphocytic leukemia: A case report. Biological Therapy of Lymphoma 8(4):6-9, 2005.

Abstracts

1. Gibson A, Sukhumalchandra P, Kerros C, Qiao N, Phillips A, Zhang M, Alkoutami S, Semelsberger S, Lu Y, Byers L, Tia Z, Shi C, Yan J, Zha D, Marinos A, Sergeeva A, He H, St. John L, Molldrem J, AlAtrash G. Cross-presented serine proteases as immunotherapy targets for lung cancer and osteosarcoma. Proceedings of the American Association for Cancer Research Annual Meeting 2023 83(7):nr 2995, 2023.
2. Carmona SN, Saengboon S, Bashir Q, Al-Atrash G, Cox N, Borthakur G, Vickers MR, Ramdial J, Kebriaei P, Popat UR, Qazilbash MH, Shpall EJ, Champlin RE, Srour SA. Impact of Smoking on Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy 2023 Tandem Meetings of ASTCT and CIBMTR 29(2, Supplement):S147-S148, 2023.
3. Popat UR, Saliba RM, Mehta RS, Alousi AM, Al-Atrash G, Bashir Q, Chen J, Gulbis AM, Hosing CM, Im JS, Kebriaei P, Khouri IF, Kawedia JD, Marin D, Nieto Y, Olson A, Oran B, Ramdial J, Saini NY, Srour SA, Shpall EJ. Myeloablative Fractionated Busulfan Regimens in Matched Donor Transplantation. Transplantation and Cellular Therapy 2023 Tandem Meetings of ASTCT and CIBMTR 29(2, Supplement):S164-S165, 2023.
4. Popat UR, Saliba RM, Mehta RS, Alousi A, Al-Atrash G, Bashir Q, Hosing CM, Gulbis AM, Im JS, Kebriaei P, Khouri IF, Kawedia JD, Marin D, Nieto Y, Olson A, Oran B, Ramdial J, Saini NY, Shigle TL, Srour SA, Rezvani K, Qazilbash MH, Andersson BS, Shpall EJ, Champlin RE. Myeloablative Fractionated Busulfan Fludarabine and Thiotepa Regimen for Haploidentical Donor Transplantation. Transplantation and Cellular Therapy 2023 Tandem Meetings of ASTCT and CIBMTR 29(2, Supplement):S167, 2023.
5. Macaron W, Ravandi F, Kadia TM, DiNardo CD, Issa GC, Daver N, Wang SA, Jorgensen JL, Patel K, Loghavi S, Knopleva M, Yilmaz M, Jabbour E, Maiti A, Abbas HA, Shpall EJ, Popat UR, Alatrash G, Pierce SA, Kantarjian H, Short N. Clinical Outcomes and Impact of Therapeutic Intervention in Patients (pts) with Acute Myeloid Leukemia (AML) with Recurrence of Measurable Residual Disease (MRD) after Achievement of MRD-Negative Remission. Blood 2022 ASH Annual Meeting 140(Supplement 1):543-545, 2022.
6. Li X, Deng Q, Henderson J, Watson G, Deaton L, Cain T, Fayad L, Padmanabhan S, Hagemeister FB, Nastoupil LJ, Fowler NH, Westin J, Steiner R, Nair R, Ahmed S, Alatrash G, Neelapu SS, Strati P, Green MR. Targetable Cellular Etiology of Prolonged Cytopenia Following CD19 CAR T-Cell TherapyClinically Relevant Abstract. Blood 2022 ASH Annual Meeting 140(Supplement 1):4502-4503, 2022.
7. Mehta RS, Saliba RM, Alousi AM, Alatrash G, Bashir Q, Hosing C, Kebriaei P, Khouri IF, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial JL, Rondon G, Srour SA, Rezvani K, Champlin RE, Shpall EJ, Cao K. HLA B-Leader Mismatch Is Associated with Poor Outcomes in NIMA/NIPA Mismatched Haploidentical Sibling Donor HCT. Blood 2022 ASH Annual Meeting 140(Supplement 1):4880-4881, 2022.
8. Yan J, Tian Z, Shi C, Zhang M, Sukhumalchandra P, Yang G, Chang QE, you J, Cui M, Shi Q, Philip A, Qiao N, Sergeeva A, St John L, He H, Zha D, Molldrem JJ, Alatrash G. Targeting Myeloid Leukemia Using Novel TCR-like Chimeric Antigen Receptor-T Cells Against Cathepsin G. Blood 2022 ASH Annual Meeting 140(Supplement 1):7392-7393, 2022.
9. Ramdial JL, Clemente-Sevilla L, Soebbing D, Dabaja BS, Thall PF, Alatrash G, Alousi AM, Mehta RS, Popat UR, Kebriaei P, Oran B, Rezvani K, Shpall EJ, Champlin RE. A Phase II Clinical Trial of “Off-the-Shelf” NK Cells with Allogeneic Stem Cell Transplantation to Decrease Disease Relapse in Patients with High-Risk Myeloid Malignancies. Blood 2022 ASH Annual Meeting 140(Supplement 1):7484-7485, 2022.
10. Mehta RS, Saliba RM, Alousi AM, Alatrash G, Bashir Q, Hosing C, Kebriaei P, Khouri IF, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial JL, Rondon G, Srour SA, Rezvani K, Champlin RE, Shpall EJ, Cao K. Son Vs Daughter Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis. Blood 2022 ASH Annual Meeting 140(Supplement 1):7649-7650, 2022.
11. Yeh J, Saliba RM, Wang C, Fang Z, Figgins B, Ahmed S, Yilmaz M, Daver N, Mehta RS, Alatrash G, Marin D, Popat UR, Champlin RE, Shpall EJ, Oran B. Efficacy and Safety of Gilteritinib Vs. Sorafenib As Post-Transplant Maintenance in Patients with FLT3-ITD Acute Myeloid Leukemia. Blood 2022 ASH Annual Meeting 140(Supplement 1):7686-7688, 2022.
12. Baran N, Patel S, Ramage C, Lodi A, Ortiz JE, Dhungana Y, Collins M, Skwarska A, Weng C, Hayes K, Zeng Z, Cooper L, Davis RE, Alatrash G, Marszalek JR, Yu J, Bhattacharya PK, Tiziana S, Konopleva M. Lipophagy As a Mechanism of Resistance in T-ALL Following Energetic Crisis Induced By Oxphos/MCT1 Blockade: Strategies to Eradicate Residual Disease. Blood 2022 ASH Annual Meeting 140(Supplement 1):8831-8832, 2022.
13. Zeiser R, Schmid C, Alatrash G, Ram R, Wu Y, Weber HJJ, Grzesiak S, Eldjerou LK, Craddock C. Siremadlin Monotherapy and in Combination with Donor Lymphocyte Infusion for Patients with Acute Myeloid Leukemia Post Allogeneic Stem Cell Transplantation Who Are in Complete Remission but at High Risk for Relapse. Blood 2022 ASH Annual Meeting 140(Supplement 1):8944-8945, 2022.
14. Sergeeva A, He H, St John L, Kerros C, Yu L, Vedia RA, Gonzalez VR, Lu S, Alatrash G, Cox K, Clise-Dwyer K, Yang SP, Lizee G, Vien L, Bover L, Ma Q, Chokshi M, Bao G, You J, Molldrem JJ. Humanized T Cell Receptor-like Antibody Hu8F4 Reduces Leukemia By Fc-Mediated Mechanism. Blood 2022 ASH Annual Meeting 140(Supplement 1):9061-9062, 2022.
15. Desai P, Wang B, Jelloul FZ, Alatrash G, Baran N, Deng Q, Green MR, Daver N, Konopleva M, Futreal A, Hao D, Abbas HA. Single-Cell Profiling of CD8 Landscape in Treatment Naïve and Relapsed/Refractory AML Patients Reveals Distinct Effector Cellular States Predictive of Outcomes. Blood 2022 ASH Annual Meeting 140(Supplement 1):9144-9145, 2022.
16. Mehta RS, Saliba RM, Alousi AM, Alatrash G, Bashir Q, Kebriaei P, Khouri IF, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial JL, Rondon G, Srour SA, Rezvani K, Champlin RE, Shpall EJ, Cao K. Mother Vs Father Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis. Blood 2022 ASH Annual Meeting 140(Supplement 1):10530-10531, 2022.
17. Pasvolsky O, Saliba RM, Popat UR, Alousi AM, Mehta RS, Yeh J, Alatrash G, Masood A, Ramdial JL, Rondon G, Kebriaei P, Champlin RE, Shpall EJ, Oran B. Efficacy of Azacitidine Post-Transplant Maintenance for FLT3-Negative Acute Myeloid Leukemia and Myelodysplastic Syndrome. Blood 2022 ASH Annual Meeting 140(Supplement 1):10550–10551, 2022.
18. Oran B, Champlin RE, Thall PF, McCarty JM, Zhang W, Marin D, Mehta RS, Alousi AM, Alatrash G, Popat UR, Kantarjian H, Bashir Q, Shpall EJ, Konopleva M. Phase II Trial of Venetoclax (Ven) in Combination with Azacitidine (AZA) As Maintenance Therapy for High-Risk Acute Leukemia Following Allogeneic Stem Cell Transplantation (SCT). Blood 2022 ASH Annual Meeting 140(Supplement 1):10561–10562, 2022.
19. Ozcan G, Popat UR, Kebriaei P, Alousi AM, Alatrash G, Bashir Q, Mehta RS, Ramdial JL, Rondon G, Shpall EJ, Champlin RE, Oran B. Transplant Outcomes for TP53 AML and MDS in a Contemporary Era. Blood 2022 ASH Annual Meeting 140(Supplement 1):10620–10621, 2022.
20. Al-Atrash G, Craddock C, Schmid C, Xu Y, Weber HJ, Eldjerou L, Weber S, Widmer L, Zeiser R. Patients at High Risk of Relapse Post-Transplant: A Phase 1 Study Design With a Novel Treatment Strategy Using the Estimand Framework. Clin Lymphoma Myeloma Leuk 2022 SOHO Annual Meeting 22(Supplement 2):S216-S217, 2022.
21. Popat UR, Mehta RS, Thall P, Bassett R, Alousi AM, Al-Atrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Marin D, Nieto Y, Olson A, Oran B, Ramdial J, Saini NY, Srour SA, Valdez BC, Rezvani K, Qazilbash MH, Daver N, Ravandi F, Shpall EJ, Champlin RE, Andersson BS. Myeloablative Fractionated Busulfan Conditioning Regimen with Sorafenib in Patients with AML: Results of Phase I Clinical Trial. Transplantation and Cellular Therapy 2022 Tandem Meetings of ASTCT and CIBMTR 28(3, Supplement):S78-S79, 2022.
22. Popat UR, Mehta RS, Bassett R, Alousi AM, Al-Atrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Kawedia JD, Khouri IF, Marin D, Nieto Y, Olson A, Oran B, Ramdial J, Saini NY, Srour SA, Valdez BC, Rezvani K, Qazilbash MH, Kadia TM, Kantarjian H, Shpall EJ, Champlin RE, Andersson BS. Post-Transplant Cyclophosphamide Versus Tacrolimus and Methotrexate to Prevent Graft-Versus-Host Disease in Recipients of Matched Donor Transplantation: Comparison of Sequential Cohorts in a Prospective Trial. Transplantation and Cellular Therapy 2022 Tandem Meetings of ASTCT and CIBMTR 28(3, Supplement):S293, 2022.
23. Popat UR, Mehta RS, Bassett R, Alousi AM, Al-Atrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Gulbis AM, Marin D, Nieto Y, Olson A, Oran B, Ramdial J, Saini NY, Srour SA, Valdez BC, Rezvani K, Qazilbash MH, Kadia TM, Konopleva M, Shpall EJ, Andersson BS, Champlin RE. Myeloablative Fractionated Busulfan Conditioning Regimen with Venetoclax in Patients with AML/MDS: Prospective Phase II Clinical Trial. Transplantation and Cellular Therapy 2022 Tandem Meetings of ASTCT and CIBMTR 28(3, Supplement):S82-S83, 2022.
24. Popat UR, Mehta RS, Bassett R, Alousi AM, Al-Atrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Kawedia JD, Khouri IF, Marin D, Nieto Y, Olson A, Oran B, Ramdial J, Saini NY, Srour SA, Rezvani K, Qazilbash MH, Shpall EJ, Andersson BS, Champlin RE. Optimizing Myeloablative Fractionated Busulfan, Fludarabine and Thiotepa Regimen: Results of Two Parallel Cohorts in a Phase 2 Prospective Clinical Trial. Transplantation and Cellular Therapy 2022 Tandem Meetings of ASTCT and CIBMTR 28(3, Supplement):S83-S84, 2022.
25. Popat UR, Mehta RS, Bassett R, Alousi AM, Alatrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Gulbis A, Marin D, Nieto Y, Olson AL, Oran B, Ramdial JL, Saini N, Srour SA, Valdez BC, Rezvani K, Qazilbash MH, Kadia TM, Konopleva M, Shpall EJ, Andersson BS, Champlin RE. Myeloablative Fractionated Busulfan Conditioning Regimen with Venetoclax in Patients with AML/MDS: Prospective Phase II Clinical Trial. Blood 2021 ASH Annual Meeting 138(Supplement 1):2879, 2021.
26. Stein EM, Chromik J, Carpio C, Mous R, Kiladjian JJ, Alatrash G, Curti A, Craddock C, Schmid C, Zeiser R, Eldjerou LK, Weber HJJ, Fabre C, Scott J, DeAngelo DJ. Siremadlin (HDM201) Is Well Tolerated and Demonstrates Clinical Activity in Patients with Acute Myeloid Leukemia Who Have Relapsed after Allogeneic Stem Cell Transplantation: A Subset Analysis of Safety and Preliminary Efficacy. Blood 2021 ASH Annual Meeting 138(Supplement 1):3417, 2021.
27. Popat UR, Bassett R, Thall PF, Alousi AM, Alatrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Marin D, Nieto Y, Olson AL, Oran B, Ramdial JL, Saini N, Srour SA, Valdez BC, Rezvani K, Qazilbash MH, Daver N, Ravandi F, Shpall EJ, Champlin RE, Andersson BS, Mehta RS. Myeloablative Fractionated Busulfan Conditioning Regimen with Sorafenib in Patients with AML: Results of Phase I Clinical Trial. Blood 2021 ASH Annual Meeting 138(Supplement 1):556, 2021.
28. Baran N, Patel S, Lodi A, Ortiz JE, Dhungana Y, Colins M, Skwarska A, Weng C, Ramage CL, Hayes K, Zeng Z, Davis E, Alatrash G, Marszalek JR, Yu J, Bhattacharya PK, Tiziani S, Konopleva M. Accumulation of Intracellular L-Lactate and Irreversible Disruption of Mitochondrial Membrane Potential upon Dual Inhibition of Oxphos and Lactate Transporter MCT-1 Induce Synthetic Lethality in T-ALL Via Mitochondrial Exhaustion. Blood 2021 ASH Annual Meeting 138(Supplement 1):680, 2021.
29. Al-Juhaishi T, Malek AE, Milton DR, Ramdial JL, Daher M, Olson AL, Srour SA, Alatrash G, Oran B, Mehta RS, Khouri IF, Bashir Q, Shah N, Ciurea SO, Rondon G, Maadani F, Hosing C, Marin D, Kebriaei P, Rezvani K, Nieto Y, Anderlini P, Alousi AM, Qazilbash MH, Popat UR, Champlin RE, Shpall EJ, Mulanovich V, Ahmed S. Incidence and Outcomes of Toxoplasma Reactivation in Patients with Hematologic Diseases after Allogeneic Hematopoietic Stem Cell Transplantation. Blood 2021 ASH Annual Meeting 138(Supplement 1):1779, 2021.
30. Popat UR, Mehta RS, Bassett R, Alousi AM, Alatrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Kawedia JD, Khouri IF, Marin D, Nieto Y, Olson AL, Oran B, Ramdial JL, Saini N, Srour SA, Rezvani K, Qazilbash MH, Shpall EJ, Andersson BS, Champlin RE. Optimizing Myeloablative Fractionated Busulfan, Fludarabine and Thiotepa Regimen: Results of Two Parallel Cohorts in a Phase 2 Prospective Clinical Trial. Blood 2021 ASH Annual Meeting 138(Supplement 1):1802, 2021.
31. Popat UR, Mehta RS, Bassett R, Alousi AM, Alatrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Kawedia JD, Khouri IF, Marin D, Nieto Y, Olson AL, Oran B, Ramdial JL, Saini N, Srour SA, Valdez BC, Rezvani K, Qazilbash MH, Kadia TM, Kantarjian H, Shpall EJ, Champlin RE, Andersson BS. Post-Transplant Cyclophosphamide Versus Tacrolimus and Methotrexate to Prevent Graft-Versus-Host Disease in Recipients of Matched Donor Transplantation: Comparison of Sequential Cohorts in a Prospective Trial. Blood 2021 ASH Annual Meeting 138(Supplement 1):1803, 2021.
32. Gibson A, Zhang M, Sukhumalchandra P, Philips AV, Qiao N, Perakis AA, Kerros C, St John L, Clise-Dwyer K, Lu S, Ma Q, Molldrem JJ, Alatrash G. Pembrolizumab in Combination with Antigen-Specific Cytotoxic T Lymphocytes Enhances Killing of Acute Myeloid Leukemia. Blood 2021 ASH Annual Meeting 138(Supplement 1):2775, 2021.
33. Mehta RS, Bassett R, Olson A, Chen J, Ganesh C, Alousi A, Anderlini P, Al-Atrash G, Bashir Q, Ciurea S, Hosing C, Im J, Kebriaei P, Khouri I, Marin D, Molldrem J, Nieto Y, Oran B, Rezvani K, Qazilbash M, Srour S, Shpall E, Champlin R, Andersson B, Popat U. Post-Transplant Cyclophosphamide in HLA-Matched and Haploidentical Transplant Recipients Receiving a Myeloablative Fractionated Busulfan Conditioning Regimen: Results of a Phase II Study. Clin Lymphoma Myeloma Leuk 2021 SOHO Annual Meeting 21(Supplement 1):S258, 2021. e-Pub 2021.
34. Trujillo-Ocampo A, Cho HW, Lee SE, Zhao M, Al-Atrash G, Molldrem JJ, Im JS. Cord-Derived Human Invariant Natural Killer T Cells Are Enriched with NKT10 Subsets and Ameliorate Xenograft Graft Versus Host Disease. Transplantation and Cellular Therapy 2021 TCT Meetings of ASTCT and CIBMTR 27(3):S251-S252, 2021.
35. Herbrich S, Baran N, Al-Atrash G, Davis E, Zha D, Konopleva M. Overexpression of CD200 Is a Stem Cell-Specific Mechanism of Immune Escape in AML. Blood 2020 ASH Annual Meeting 136(Supplement 1):14-15, 2020.
36. Mehta R, Basset R, Chen J, Valdez Benigno, Kawedia J, Alousi A, Al-Atrash G, Bashir Q, Ciurea S, Hosing C, Im J, Kebriaei P, Olson A, Oran B, Qazilbash M, Shpall E, Champlin R, Popat U. Myeloablative Fractionated Busulfan with Fludarabine in Older Patients: Long Term Outcomes of Prospective Phase II Clinical Trial. Blood 2020 ASH Annual Meeting 136(Supplement 1):10-11, 2020.
37. Abbas H, Hao D, Tomczak K, Barrodia Praveen, Im J, Reville, Alaniz Z, Wang W, Wang R, Wang F, Takahashi, Ning J, Ding M, Matthews J, Little L, Zhang J, Basu S, Konopleva M, Garcia-Manero G, Al-Atrash G, Sharma P, Allison J, Kornblau S, Wang L, Futreal A, Daver N. Single-Cell Characterization of Acute Myeloid Leukemia (AML) and Its Microenvironment Identifies Signatures of Resistance to PD-1 Blockade Based Therapy. Blood 2020 ASH Annual Meeting 136(Supplement 1):29-31, 2020.
38. Saberian C, Abdel N, Abudayyeh A, Rafei H, Joseph J, Daher M, Gruschkus S, Knape C, Whited L, Gulbis A, Marcotulli M, Rondon G, Popat U, Mehta R, Konopleva M, Oran B, Ohanian M, Ravandi F, Garcia-Manero G, Alousi A, Daver N, Champlin R, Diab A, Al-Atrash G. Lower Risk of Graft Versus Host Disease after Exposure to Checkpoint Inhibitors with the Use of Post-Transplant Cyclophosphamide Prophylaxis. Blood 2020 ASH Annual Meeting 136(Supplement 1), 2020.
39. Oran B, Ciurea S, Mehta R, Alousi A, Rondon G, Popat U, Marin D, Daher M, Im J, Kebriaei P, Al-Atrash G, Champlin R,. Transplant Outcomes with Fludarabine and Melphalan in High Risk AML Patients By Donor Types. Blood 2020 ASH Annual Meeting 136(Supplement 1):20-21, 2020.
40. Zeidan A, Boddu P, Wood B, Zelterman D, Little R, Ivy P, Caldwell A, Sanchez-Espiridion B, Al-Atrash G, Sharon E, Radich J. Blast MRD AML-2: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MDR) in Acute Myeloid Leukemia (AML) 2- a Randomized Phase 2 Study of the Venetoclax, Azacitidine, and Pembrolizumab Versus Venetoclax and Azacitidine As First Line Therapy in Older Patients with AML Who Are Ineligible or Who Refuse Intensive Chemotherapy. Blood 2020 ASH Annual Meeting 136(Supplement 1):11-20, 2020.
41. Lee S, Wang F, Trujillo-Ocampo A, Ruiz-Vazquez W, Hyun-Woo Cho, Takahashi K, Al-Atrash G, Molldrem J, Champlin R, Daver N, Kantarjian H, Futreal A, Garcia-Manero, Im J. Immunologic Predictors for Clinical Responses in Patients with Myelodysplastic Syndromes Treated with Immune Checkpoint Blockade. Blood 2020 ASH Annual Meeting 136(Supplement 1):4, 2020.
42. Oran B, Alatrash G, Alousi AM, Mehta RS, Hosing C, Popat UR, Im JS, McCarty JM, Ramos JD, Keer HN, Thall PF, Champlin RE. Maintenance Treatment with Guadecitabine (SGI-110) in High Risk MDS and AML Patients after Allogeneic Stem Cell Transplantation. Blood 2020 ASH Annual Meeting 136(Supplement 1):29-30, 2020.
43. Mukherjee A, Milton DR, Jabbour E, Daver N, Gulbis A, Ledesma G, Konopleva M, DiNardo CD, Ravandi F, Kadia TM, Alatrash G, Alousi AM, Daher M, Marin D, Olson AL, Oran B, Kebriaei P, Saini N, Srour SA, Popat UR, Im JS, |Mehta R, Rondon G, Kantarjian HM, Champlin RE, Khouri IF. Risk of Gvhd and Survival in Patients with Acute Leukemia Who Were Bridged to Allogeneic Stem Cell Transplantation (alloSCT) with Venetoclax- Based Therapy. Blood 2020 ASH Annual Meeting 136(Supplement 1):13-14, 2020.
44. Zeidan AM, Boddu PC, Wood BL, Zelterman D, Little RF, Ivy SP, Caldwell A, Sanchez-Espiridion B, Alatrash G, Sharon E, Radich JP. Blast MRD AML-1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia (AML) 1- an Investigator-Initiated, CTEP-Sponsored, Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination with Conventional Intensive Chemotherapy (IC) As Frontline Therapy in Patients with Acute Myeloid Leukemia (AML). Blood 2020 ASH Annual Meeting 136(Supplement 1):15, 2020.
45. Yalniz F, Saliba R, Greenbaum U, Ramdial J, Alousi A, Joseph J, Olson A, Alatrash G, Marin D, Rezvani K, Hosing C, Im J, Shpall E, Mehta R, Qazilbash M, Popat U, Oran B, Champlin R, Kebriaei P. Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Patients with Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 2020 SOHO Annual Meeting 20(Supplement 1):S202, 2020. e-Pub 2020.
46. Yam C, Alatrash G, Yen EY, Garber H, Philips AV, Huo L, Yang F, Bassett RL, Sun X, Cuentas ERP, Symmans WF, Seth S, White JB, Rauch GM, Damodaran S, Litton JK, Wargo JA, Hortobagyi GN, Moulder SL, Mittendorf EA. Immune phenotype and response to neoadjuvant systemic therapy (NAST) in triple negative breast cancer (TNBC). 2020 ASCO Virtual Scientific Program 38(15):Suppl.509, 2020.
47. Joseph J, Milton DR, Chen J, Alatrash G, Alousi AM, Bashir, Q, Ciurea SO, Daher M, Im JS, Mehta RS, Oran B, Olson AL, Saini N, Srour SA, Andersson B, Champlin RE, Popat UR. Myeloablative fludarabine and busulfan regimen in myelofibrosis: Long term outcomes and analysis of prognostic factors. 2020 ASCO Virtual Scientific Program 38(15):Suppl.e19520, 2020.
48. Popat UR, Mehta RS, Bassett R, Olson A, Chen J, Ganesh C, Alousi AM, Anderlini P, Alatrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri IF, Marin D, Nieto Y, Oran B, Saini N, Srour SA, Rezvani K, Qazilbash MH, Molldrem JJ, Shpall EJ, Champlin RE, Andersson BS. Myeloablative Fractionated Busulfan Conditioning Regimen in Older Patients: Results of a Phase II Study. Biol Blood Marrow Transplant 2020 TCT Meetings of ASTCT & CIBMTR 26(3, Supplement):S6-S7, 2020.
49. Popat UR, Saliba RM, Mehta RS, Olson A, Chen J, Ganesh C, Woodworth G, McMullin B, Alousi AM, Anderlini P, Alatrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri IF, Marin D, Nieto Y, Oran B, Saini NY, Srour SA, Rezvani K, Qazilbash MH, Molldrem JJ. Comparison of Post-Transplant Cyclophosphamide and Tacrolimus and Methotrexate Graft Versus Host Disease Prophylaxis in AML Patients Receiving Myeloablative Fractionated Busulfan Conditioning Regimen. Biol Blood Marrow Transplant 2020 TCT Meetings of ASTCT & CIBMTR 26(3, Supplement):S125, 2020.
50. Goldberg J, Qiao N, Gross B, Meric-Bernstam F, Guerriero J, Chen K, Philips AV, Peoples GE, Alatrash G, Mittendorf EA. ESR1 mutations provide novel targets for breast cancer immunotherapy. 2020 ASCO Virtual Scientific Program 38(15):Suppl.3135, 2020.
51. Champlin RE, Popat U, Oran B, Ciurea SO, Kebriaei P, Alousi AM, Alatrash G, Bashir Q, Khouri IF, Hosing C, Anderlini P, Jones RB, Marin D, Mehta R, Nieto Y, Olson AL, Qazilbash MH, Rezvani K, Shpall EJ, Chen J, Rondon G, McMullin B, Al Jahdami VP, Kawedia J, Valdez BC, Ma J, Thall PF, Andersson BS. A Randomized Study of Fludarabine-Clofarabine Vs Fludarabine Alone Combined with Busulfan and Allogeneic Hematopoietic Transplantation for AML and MDS. Blood 2019 ASH Annual Meeting 134(Supplement_1):257, 2019.
52. Popat U, Mehta RS, Bassett R, Olson AL, Chen J, Ganesh C, Alousi AM, Anderlini P, Alatrash G, Bashir Q, Ciurea SO, Hosing C, Im JS, Kebriaei P, Khouri IF, Marin D, Nieto Y, Oran B, Saini N, Srour S, Rezvani K, Qazilbash M, Molldrem JJ, Shpall EJ, Andersson BS, Champlin RE. Myeloablative Fractionated Busulfan Conditioning Regimen in Older Patients: Results of a Phase II Study. Blood 2019 ASH Annual Meeting 134(Supplement_1):256, 2019.
53. Popat U, Saliba RM, Mehta RS, Olson AL, Chen J, Ganesh C, Rondon G, Woodworth G, McMullin B, Alousi AM, Anderlini P, Alatrash G, Bashir Q, Ciurea SO, Hosing C, Im JS, Kebriaei P, Khouri IF, Marin D, Nieto Y, Oran B, Saini N, Srour S, Rezvani K, Qazilbash MH, Molldrem JJ, Shpall EJ, Andersson BS, Champlin RE. Reduced Severe aGVHD and Improved Survival Using Post Transplant Cyclophosphamide/Tacrolimus/Methotrexate Graft Versus Host Disease Prophylaxis in AML Patients Receiving Myeloablative Fractionated Busulfan Conditioning Regimen. Blood 2019 ASH Annual Meeting 134(Supplement_1):3296, 2019.
54. Yalniz FF, Saliba RM, Yucel OK, Garcia-Manero G, Ramdial J, Popat U, Ciurea SO, Kebriaei P, Alousi AM, Alatrash G, Bashir Q, Hosing C, Marin D, Mehta R, Olson AL, Rezvani K, Shpall EJ, Rondon G, Champlin RE, Oran B. Somatic Mutations Improve Risk Classification By Cytogenetic Abnormalities in Patients with Myelodysplastic Syndrome after Hematopoietic Stem Cell Transplantation. Blood 2019 ASH Annual Meeting 134(Supplement_1):512, 2019.
55. Mehta RS, Bassett R, Olson A, Chen J, Ahmed S, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri IF, Marin D, Nieto Y, Oran B, Rezvani K, Qazilbash MH, Srour SA, Molldrem JJ, Shpall EJ, Andersson BS, Champlin RE, Popat UR. Myeloablative Conditioning Using Timed Sequential Busulfan in Older Patients with Acute Myeloid Leukemia: Long Term Results of a Prospective Phase II Clinical Trial. Biol Blood Marrow Transplant 2019 TCT Meetings of ASTCT & CIBMTR 25(3, Supplement):S116-S117, 2019.
56. Popat UR, Saliba RM, Olson A, Mehta RS, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri IF, Marin D, Molldrem JJ, Nieto Y, Oran B, Qazilbash MH, Rezvani K, Champlin RE. Comparison of Tacrolimus and Post-Transplant Cyclophosphamide (PTCy) with Tacrolimus and Methotrexate (Tac/MTX) Gvhd Prophylaxis in Patients with AML Undergoing Transplantation from Matched Related or Unrelated Donors. Biol Blood Marrow Transplant 2019 TCT Meetings of ASTCT & CIBMTR 25(3, Supplement):S235-S236, 2019.
57. Mukherjee A, Milton D, Ledesma C, Olson A, Alatrash G, Anderlini P, Alousi AM, Bashir Q, Ciurea SO, Kebriaei P, Marin D, Molldrem JJ, Oran B, Popat UR, Qazilbash MH, Rondon G, Champlin RE, Gulbis AM, Khouri IF. Influence of the Intensity of the Allogeneic Conditioning Regimen on the Risk of Hemorrhagic Cystitis (HC) in Patients Receiving Post- Transplant Cyclophosphamide (PT-Cy) As Gvhd Prophylaxis. Biol Blood Marrow Transplant 2019 TCT Meetings of ASTCT & CIBMTR 25(3,Supplement):S147-S148, 2019.
58. Popat UR, Mehta RS, Bassett R, Olson AL, Alousi AM, Anderlini P, Alatrash G, Bashir Q, Ciurea SO, Hosing C, Kebriaei P, Khouri IF, Marin D, Nieto Y, Oran B, Rezvani K, Qazilbash MH, Shpall EJ, Champlin RE, Andersson B. Post-transplant cyclophosphamide in matched and haploidentical transplant recipients receiving myeloablative timed sequential busulfan conditioning regimen: Results of a phase II study. 2019 ASCO Annual Meeting 37(15):Suppl.7007, 2019.
59. Noha Abdel-Wahab, Gheath Al-Atrash. Checkpoint Inhibitor Therapy in Solid Organ and Allogeneic Stem Cell Transplantation: Data Mining of The Truven Health Marketscan Research Database. SITC Annual Meeting, 2018.
60. Khouri IF, Milton DR, Ledesma C, Jabbour EJ, Alatrash G, Anderlini P, Alousi AM, Bashir Q, Ciurea SO, Hymes S, Marin D, Molldrem JJ, Olson AL, Oran B, Popat U, Qazilbash MH, Rondon G, Champlin RE, Gulbis A. Influence of the Intensity of the Conditioning Regimens on the Risks of Gvhd in Patients Receiving Rituximab Prophylaxis during Allogeneic Stem Cell Transplantation (alloSCT). Blood 2018 ASH Annual Meeting 132(Supplment 1):4584, 2018.
61. Khouri IF, Milton DR, Ledesma C, Erwin WD, Jabbour EJ, Alatrash G, Anderlini P, Bashir Q, Ciurea SO, Im JS, Marin D, Mehta RS, Molldrem JJ, Olson AL, Oran B, Popat U, Qazilbash MH, Rondon G, Champlin RE, Medeiros J, Gulbis A. Durability Results of Non-Myeloablative (NMA) Allogeneic Stem Cell Transplantation (alloSCT) for Relapsed Follicular Lymphoma: 17- Year Experience. Blood 2018 ASH Annual Meeting 132(Supplement 1):4651, 2018.
62. Oran B, Garcia-Manero G, Saliba RM, Alatrash G, Jabbour EJ, Popat U, Ravandi F, Kadia TM, Cortes JE, Alousi AM, Konopleva MY, DiNardo CD, Rezvani K, Alfayez M, Shpall EJ, Sharma P, Champlin RE, Kantarjian HM, Daver NG. Post Allogeneic Stem Cell Transplant (SCT) Cyclophosphamide Improves Progression Free Survival (PFS) in Pts with AML/MDS Treated with CTLA-4 or PD-1 Blockade Prior to SCT. Blood 2018 ASH Annual Meeting 132(Supplment 1):483, 2018.
63. Zhang M, Sukhumalchandra P, Philips AV, Qiao N, Kerros C, St John L, Perakis AA, Clise-Dwyer K, Mittendorf E, Daver NG, Molldrem JJ, Qing M, Alatrash G. Pembrolizumab Enhances the Anti-Leukemia Activity of Antigen Specific Cytotoxic T Lymphocytes. Blood 2018 ASH Annual Meeting 132(Supplment 1):4542, 2018.
64. Ciurea SO, Bittencourt MCB, Milton DR, Cao K, Kongtim P, Rondon G, Chen J, Konopleva MY, Ramos Perez JM, Elshazly M, Aljadayeh M, Alvarez M, Im JS, Alatrash G, Mehta RS, Popat U, Bashir Q, Oran B, Hosing C, Khouri IF, Kebriaei P, Champlin RE. Is a Matched Unrelated Donor Search Needed for All Allogeneic Transplant Candidates?. Blood |2018 ASH Annual Meeting 132(Supplment 1):3450, 2018.
65. Popat U, Mehta RS, Bassett RL, Olson AL, Chen J, Ahmed S, Alousi AM, Anderlini P, Alatrash G, Bashir Q, Ciurea SO, Hosing C, Im JS, Kebraei P, Khouri IF, Marin D, Nieto Y, Oran B, Rezvani K, Qazilbash M, Shpall EJ, Champlin RE, Andersson BS. Timed Sequential Busulfan and Post-Transplantation Cyclophosphamide in Matched and Haploidentical Transplantation: Results of a Phase II Study. Blood 2018 ASH Annual Meeting 132(Supplment 1):3373, 2018.
66. Kongtim P, Parmar S, Milton DR, Ramos Perez JM, Rondon G, Chen J, Chilkulwar AR, Altrash G, Alousi AM, Andersson BS, Im JS, Hosing C, Bashir Q, Khouri IF, Kebriaei P, Oran B, Popat U, Champlin RE, Ciurea SO. Hematopoietic Cell Transplant-Composite Risk (HCT-CR) — a Novel Prognostic Model to Predict Transplant Outcomes. Blood 2018 ASH Annual Meeting 132(Supplment 1):2141, 2018.
67. Lansford JL, Dharmasiri U, Chai S, Hunsucker SA, Bortone DS, Keating JE, Schlup IM, Glish GL, Collins EJ, Alatrash G, Molldrem JJ, Armistead PM, Vincent BG. Identification of Leukemia Associated Minor Histocompatibility Antigens through Computational Prediction and Targeted Mass Spectrometry. Blood 2017 ASH Annual Meeting 130(Supplement 1):207, 2017.
68. Gall V, Philips AV, Chawla A, Qiao N, John LS, Sukhumalchandra P, Zhang M, Molldrem JJ, Alatrash G, Mittendorf EA. Neutrophil elastase regulates PD-L1 expression in breast cancer. Proceedings of the 107th Annual Meeting of the American Association for Cancer Research (AACR), 2016.
69. Gall V, Philips AV, Qiao N, Dwyer KC, Perakis AA, Zhang M, Sukhumalchandra P, Molldrem JJ, Alatrash G, Mittendorf EA. Trastuzumab increases uptake and cross-presentation of HER2-derived antigens by dendritic cells. 107th Annual Meeting of the American Association for Cancer Research (AACR), 2016.
70. Gaballa S , Ge I, El-Fakih R, Brammer J, Wang S, Lee D, Petropoulos D, Cao K, Rondon G, Chen J, Hammerstrom A, Al-atrash G, Korbling M, Betul O, Kebriaei P, Ahmed S, Shah N, Rezvani K, Marin D, Bashir Q, Alousi A, Nieto Y, Qazilbash M, Hosing C, Popat U, Shpall EJ, Khouri K, Champlin R, Ciurea SO. Results of a two-arm phase II clinical trial using post-transplantation cyclophosphamide for prevention of graft-versus-host disease in haploidentical and mismatched unrelated donors hematopoietic stem-cell transplantation. Blood 2015 ASH Annual Meeting 126(23), 2015.
71. Alatrash G, Zhang M, Qiao N, Sukhumalchandra P, Zope M, Philips AV, Perakis A, St John L, Khouri MR, Gall V, Dwyer KC, Polan J, Molldrem JJ, Shpall EJ, Mittendorf EA. Fucosylated Antigen-Specific Cytotoxic T Lymphocytes Demonstrate Enhanced Killing of Leukemia Targets. Blood 2015 ASH Annual Meeting 126(23):1888, 2015.
72. Khouri I, Saliba R, Ledesma C, Jabbour E, Turturro F, Alatrash G, Ahmed S, Betul O, Patel K, Olson A, Marin D, Popat U, Suki T, Jorgenson J, Mederios J, Gulbis A. BFR (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning Improves Survival in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). Blood 2015 ASH Annual Meeting 126(23):2011, 2015.
73. Qiao N, Mittendorf EA, Zhang M, Sukhumalchandra P, Polan JL, Neal S, Rauf M, Gall V, Philips AV, Shpall EJ, Alatrash G. Fucosylation Enhances Activity of Cytotoxic T Lymphocytes Against Breast Cancer. SITC 2015. Journal for ImmunoTherapy of Cancer, 2015.
74. Garber Haven R, Beird Hannah, Cao Yu, Zhang Jianhua, Sargent Rachel, Lin Pei, SethSahil, Song Xingzhi, Sun Huandong, Mao Zizeng, St John Lisa, Clise-Dwyer Karen, Alatrash Gheath, Futreal P Andrew, Molldrem Jeffery J. Long-term subcional evoiution of CLL from immune selective pressure after allogenic stem cell transplant and donor lymphocyte infusion. Cancer Research, 2015.
75. Alatrash G, Sukhumalchandra P, Zhang M, Kerros C, Sergeeva A, Cernosek A, Jakher H, Zope M, Patenia R, St John L, Perakis A, Dwyer K, , Ken H, Young K, Weng J, Lu S, Mittendorf EA, Kwak L, Ma Q , Molldrem JJ. PR1 Is Cross-Presented By Multiple Myeloma Cells in Patients and Renders Multiple Myeloma Susceptible to PR1-CTL and Anti-PR1/HLA-A2 Antibody. Blood 2014 ASH Annual Meeting 124(21):2133, 2014. e-Pub 2014.
76. Alatrash G, Zhang M, Sukhumalchandra P, Qiu Y, Talukder S, Senyukov V, St. John L, He H, Sergeeva A, Roszik J, Clise-Dwyer K, Lu S, Ma Q, Mittendorf EA, Lee D, Hawke D, Lizee G, Molldrem JJ, Kornblau S. Cathepsin G Is Broadly Expressed By AML and Is an Effective Immunotherapeutic Target Against AML in Vivo. Blood 2014 ASH Annual Meeting 124(21):3761, 2014. e-Pub 2014.
77. Chawla A, Philips AV, Qiao N, Sukhumalchandra P, Kerros C, Molldrem J, Alatrash G, Mittendorf EA. Neutrophil elastase uptake by breast cancer increases anti-tumor adaptive immune response by upregulation of HLA class I molecules. Annals of Surgical Oncology 124(21), 2014.
78. Chawla A, Philips AV, Qiao N, Sukhumalchandra P, Kerros C, Alatrash G, Molldrem JJ, Mittendorf EA. Neutrophil elastase enhances adaptive immunity via increase of peptide presentation and downregulation of T cell inhibitory molecules. Proceedings of the 105th Annual Meeting of the American Association for Cancer Research (AACR) 74, 2014.
79. Mittendorf EA, Wang C, Yau P, Roman K, Wu Y, Alatrash G, Hoyt C. Multispectral imaging allows visualization and quantification of multiple immunologic cell types in breast tumor tissues. San Antonio Breast Cancer Symposium, 2014.
80. Pingali SR, Denai M, Di Stasi A, Kebriaei P, Popat U, Alousi A, Anderlini P, Parmar S, Hosing C, Andersson B, Bashir Q, Ahmed S, Oran B, Shpall EJ, Khouri I, Konopleva M, Alatrash G, Champlin R and Ciurea S. Haploidentical Transplantation For Patients With Advanced Hematologic Malignancies With Melphalan-Based Conditioning – Interim Results From a Phase II Clinical Trial. Blood 2013 ASH Annual Meeting 122(21):4523, 2013.
81. Han L, Jorgensen J, Wangg S, Huang X, Goznalez G, Brooks C, Rowinsky E, Levis M, Zhou J, Ciurea S, Alatrash A, Cortes J, Kantarjian H, Andreeff M, Ravandi F, Konopleva M. Leukemia Stem Cell Marker CD123 (IL-3R alpha) Predicts Minimal Residual Disease and Relapse, Providing a Valid Target For SL-101 In Acute Myeloid Leukemia With FLT3-ITD Mutations. Blood 2013 ASH Annual Meeting 122(21):359, 2013.
82. Qiao N, Chawla A, Alatrash G, Philips A, Peoples GE, Ponniah S, Mittendorf EA. A novel method to identify HER2-derived HLA-A2 epitopes for use in combination immunotherapy with Trastuzumab. Proceedings of the 104th Annual Meeting of the American Association for Cancer Research (AACR) 73, 2013.
83. Alatrash G, Sukhumalchandra P, Zhang M, Jakher H, Weng J, St. John L, Ruisaard K, Clise-Dwyer K, Lu S, Molldrem JJ. Multiple Myeloma Cross-Presents Neutrophil Elastase and Proteinase 3 and Becomes Susceptible to PR1-Targeting Immunotherapy. Blood 2012 ASH Annual Meering 120(21):4973, 2012.
84. Yang T, Clise-Dwyer K, St. John L, Alatrash G, Ruisaard K, Lu S, Molldrem JJ. Membrane-Associated Proteinase 3 On Granulocytes and Myeloid Leukemia Mediates Reversible Inhibition of T Cell Proliferation Associated with Altered ZAP70 and ERK Signaling. Blood 2012 ASH Annual Meering 120(21):1031, 2012.
85. Vincent B, Singh D, Wu M, Hunsucker S, Alatrash G, Ruisaard K, Sukhumalchandra P, Clise-Dwyer K, Serody J, Prins J, Molldrem JJ, Armistead P. RNA-Seq Expression Profiling of AML Stem Cells Reveals Differential Expression of Lineage Differentiation Markers and Novel Splice Variants. Blood 2012 ASH Annual Meering 120(21):2502, 2012.
86. Tian-Hui Yang, Karen Clise-Dwyer, Gheath Alatrash, Kathryn Ruisaard, Shoudan Liang, and Jeffrey J. Molldrem. Membrane-Associated Proteinase 3 on Granulocytes and Myeloid Leukemia Mediates Reversible Inhibition of T Cell Proliferation. Blood 2011 ASH Annual Meeting 118(21):1916, 2011.
87. Anna Sergeeva, Hong He, Kathryn Ruisaard, Karen Clise-Dwyer, Lisa S St. John, Rebecca Patenia, Pariya Sukhumalchandra, Gheath Alatrash, William K Decker, Elizabeth J Shpall, M. James You, Qing Ma, and Jeffrey J. Molldrem. Treatment with 8F4, An Anti-PR1/HLA-A2 T Cell Receptor-Like Antibody, Reduces Established Acute Myeloid Leukemia and Eliminates Leukemia Stem Cells in Mice. Blood 2011 ASH Annual Meeting 118(21):766, 2011.
88. Mao Zhang, Pariya Sukhumalchandra, Atim A. Enyenihi, Lisa S St. John, Sally A. Hunsucker, Kathryn Ruisaard, Zein Al Atrache, Patricia A Ropp, Tania Rodriguez-Cruz, Elizabeth Mittendorf, Gregory Lizee, Karen Clise-Dwyer, Sijie Lu, Gary L. Glish, Jeffrey J. Molldrem, Paul M Armistead, and Gheath Alatrash. A Novel HLA-A2 Restricted Peptide Derived From Cathepsin G Is An Effective Immunotherapeutic Target for Myeloid Leukemia. Blood 2011 ASH Annual Meeting 118(21):2986, 2011.
89. Colleen McGary, Atim A. Enyenihi, Sally A. Hunsucker, Patricia A. Ropp, Tania Rodriguez-Cruz, Gregory Lizee, Gheath Alatrash, Gary L. Glish, and Paul M. Armistead. Identification of Leukemia Associated Antigens From ANKRD17 and CDK4 Using Mass Spectrometry Based Screening,. Blood 2011 ASH Annual Meeting 118(21):4020, 2011.
90. Mittendorf EA, Alatrash G, Qiao N, Sukhumalchandra P, Xiao H, Molldrem JJ. Evaluation of cyclin E as a novel target for breast cancer immunotherapy. Journal of Surgical Research 165(2):181, 2011.
91. Chiattone A, Saliba R, Andersson B, Giralt S, Sharma M, Rondon G, Kebriaei P, Hosing C, Popat U, Parmar S, Alatrash G, Bashir Q, Chen U, Yuen C, Chiattone, V, Champlin R, De Lima M. Treatment of AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Using Low-Dose Azacitidine (AZA). Blood 2010 ASH Annual Meeting 116(21):3445, 2010.
92. Alatrash G, Ono Y, Sergeeva A, Sukhumalchandra P, Zhang M, Quintanilla K, Armistead P, He H, Rodriguez-Cruz T, Clise-Dwyer K, Wieder E, Lizee G, Lu S, Molldrem J. Peripheral Tolerance to PR1 Is Maintained After Uptake of Soluble Proteinas-3 and Neutrophil Elastase. Blood 2010 ASH Annual Meeting 116(21):4301, 2010.
93. Alatrash G, Mittendorf E, Sergeeva A, Sukhumalchandra P, Qiao N, Quintanilla K, Zhang M, Lu S, Clise-Dwyer K, Molldrem J. Soluble Inflammatory Mediators Proteinase-3 and Neutrophil Elastase Are Targeted by PR1-Specific Immunotherapy After Cellular Uptake and Cross Presentation of PR1 Peptide by Breast Cancer Cells. Blood 2010 ASH Annual Meeting 116(21):2089, 2010.
94. Mittendorf E, Alatrash G, Qiao N, Sukhumalchandra P, Lu S, Quintanilla K, Clise-Dwyer K, Molldrem J. Cellular uptake of soluble neutrophil elastase increases cyclin E (CCNE) isoform expression and significantly augments susceptibility of breast cancer cells to cytolysis by CCNE-specific cytotoxic T lymphocytes. Blood 2010 ASH Annual Meeting 116(21):2090, 2010.
95. Yang T, Alatrash G, Clise-Dwyer K, Quintanilla K, Lu S, Molldrem J. Proteinase 3 Mediates Enzyme-Independent Reversible Inhibition of CD4 and CD8 T Cell Proliferation by Blocking G1-S Transition. Blood 2010 ASH Annual Meeting 116(21):2099, 2010.
96. Alatrash G, Pelosini M, Saliba R, Rondon G, Weiqing Z, Giralt S, Kebriaaei P, Alousi A, Khouri I, Champlin R, de Lima M. Post-hematopoietic stem cell transplantation (HSCT) outcomes in patients with AML transplanted prior to achieving platelet recovery. American Society of Blood and Marrow Transplantation (ASBMT) annual meeting. Biology of Blood and Marrow Transplantation 15(2):58, 2009.
97. Alatrash G, Andersson B, Pelosini M, Rondon G, Qazilbash M, Giralt S, de Padua Silva L, Hosing C, Kebriaei P, Zhang W, Saliba R, Champlin R, de Lima M. Allogenieic hematopoietic stem cell transplant (HSCT) for patients in the 6th and 7th decades of life with AML or MDS using myeloablative, reduced toxicity IV Busulfan/Fludarabine (BuFlu) conditioning regimen. American Society of Blood and Marrow Transplantation (ASBMT) annual meeting. Biology of Blood and Marrow Transplantation 15(2):106, 2009.
98. Alatrash G, Pelosini M, Saliba RM, Rondon G, Zhang W, Giralt S, Kebriaei P, Alousi A, Khouri IF, Champlin RE, De Lima M. Platelet Recovery Prior to Stem Cell Transplantation Predicts for Post- Transplant Outcomes in Patients with AML. Blood 2008 ASH Annual Meeting 112(11):3000, 2008.
99. Alatrash G, Andersson BS, Pelosini M, Rondon G, Qazilbash MH, Giralt S, de Padua Silva L, Hosing C, Kebriaei P, Zhang W Saliba R, Champlin RE, De Lima M. Myeloablative, reduced toxicity IV Busulfan/Fludarabine (BuFlu) and allogeneic hematopoietic stem cell transplant (HSCT) for patients in the 6th and 7th decades of life with AML or MDS. Blood 2008 ASH Annual Meeting 112(11):2999, 2008.
100. Sergeeva A, Lu S, Wygant JN, Alatrash G, Quintanilla K, Molldrem JJ. Direct Visualization of PR1/HLA-A2 on the Membrane of HLAA2+ CD13+CD33+ Myeloid Leukemia Blasts by a Novel Monoclonal Antibody. Blood 2008 ASH Annual Meeting 112(11):2545, 2008.
101. Alatrash G, Vence L, Woodward W, Ueno N, Molldrem JJ. Leukemia-associated primary granule proteins (PGPs) elastase-2 and proteinase-3 are aberrantly expressed in solid tumors: a potential therapeutic target for PR1-directed immunotherapy. Blood 2008 ASH Annual Meeting 112(11):5440, 2008.
102. Alatrash G, Ono Y, Lu S, Sergeeva A, Sukhumalchandra P, Wang C, Wieder E, Molldrem JJ. Mistrafficking of primary granule proteins (PGPs) in leukemia simultaneously promotes PGP cross-priming and increases susceptibility to CTL killing. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research (AACR) 68, 2008.
103. Alatrash G, Ono Y, Lu S, Sergeeva A, Wang C, Wieder E, Molldrem JJ. Aberrant subcellular localization of azurophil granule proteins in myeloid leukemia favors peptide antigen presentation on MHC-I and susceptibility to killing by cytotoxic T lymphocytes. Blood 2007 ASH Annual Meeting 110(11):4900, 2007.
104. Alatrash G, Keating MJ, O'Brien S, Wang X, Manshouri T, Faderl S, Ferrajoli A, Kantarjian HM, Lerner S, Wierda WG. Circulating CD52 and CD20 levels predict for progression and survival in patients with CLL treated with Fludarabine (F), Cyclophosphamide (C), and Rituximab (FCR). Blood 2006 ASH Annual Meeting 108(11):2330, 2006.
105. Alatrash G, Hutson TE, Nemec C, Mekhail T, Richmond A, Molto L, Elson P, Tannenbaum C, Finke J, Olencki T, Bukowski RM. Toxicity and immunologic effects of subcutaneously (SC) administered IL-12 and IFN-a2b in patients (Pts) with metastatic renal cell carcinoma (RCC) or malignant melanoma (MM). American Society of Clinical Oncology (ASCO) annual meeting. Journal of Clinical Oncology, 2003.
106. Alatrash G, Kitson RP, Kim MH, Mazar AP, Goldfarb RH. Urokinase plasminogen activator and its receptor in NK cells: Contribution to extacelluar matrix degradation and impact on NK cell accumulation into cancer metastases. Federation of American Societies for Experimental Biology (FASEB) 14(6):A1024, 2000.

Book Chapters

1. Alatrash G, Molldrem JJ. Tumor-associated antigens. In: Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation Models in Discovery and Translation. Elsevier, 143-159, 2013.
2. Alatrash G, de Lima M. Stem Cell Transplant for AML. In: Leukemias: Principles and Practice of Therapy. Blackwell Publishing, 2008.
3. Alatrash G, Bukowski R, Tannenbaum C, Finke J. Interleukins. In: Cancer Chemotherapy and Biotherapy: Principles and Practice. Lippincott Williams and Wilkins, 2006.